{"id":69397,"date":"2026-07-06T11:19:16","date_gmt":"2026-07-06T03:19:16","guid":{"rendered":"https:\/\/flcube.com\/?p=69397"},"modified":"2026-07-06T11:23:13","modified_gmt":"2026-07-06T03:23:13","slug":"hua-medicine-partners-with-gemvcare-on-real-world-clinical-study-for-dorzagliatin-in-precision-diabetes-management","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69397","title":{"rendered":"Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hua Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2552:HKG\">HKG: 2552<\/a>) announced a research collaboration agreement with <strong>GemVCare (GVC)<\/strong>, a Hong Kong-based biotechnology company, to conduct a real-world clinical study focused on <strong>precision diabetes management<\/strong> using <strong>dorzagliatin<\/strong>, a first-in-class <strong>glucokinase activator (GKA)<\/strong> anti-diabetic drug, combined with GVC&#8217;s precision diagnostic technology.<\/p>\n\n\n\n<h2 id=\"h-collaboration-overview\" class=\"wp-block-heading\">Collaboration Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Hua Medicine (HKG: 2552) &amp; GemVCare (GVC)<\/td><\/tr><tr><td><strong>Study Type<\/strong><\/td><td>Real-world clinical study<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Precision diabetes management for type 2 diabetes<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Dorzagliatin (MYHOMSIS)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>First-in-class glucokinase activator (GKA)<\/td><\/tr><tr><td><strong>Diagnostic Component<\/strong><\/td><td>GVC&#8217;s precision diagnostic technology<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>Hong Kong market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Dorzagliatin (trade name: MYHOMSIS)<\/li>\n\n\n\n<li><strong>Target:<\/strong> Glucokinase (glucose sensor)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First-in-class <strong>glucokinase activator<\/strong> that improves glucose sensitivity and addresses blood glucose homeostasis regulation failure in type 2 diabetes patients<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong><\/li>\n\n\n\n<li>Approved by China NMPA (30 Sep 2022) for monotherapy or combination with metformin<\/li>\n\n\n\n<li>Approved in Hong Kong (Feb 2026)<\/li>\n\n\n\n<li>Approved in Macau (Jun 2026)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-milestones-timeline\" class=\"wp-block-heading\">Regulatory Milestones Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Milestone<\/th><th>Jurisdiction<\/th><\/tr><\/thead><tbody><tr><td><strong>30 Sep 2022<\/strong><\/td><td>Marketing approval for adult type 2 diabetes (mono\/combination therapy)<\/td><td>China (NMPA)<\/td><\/tr><tr><td><strong>Feb 2026<\/strong><\/td><td>Marketing approval granted<\/td><td>Hong Kong<\/td><\/tr><tr><td><strong>Jun 2026<\/strong><\/td><td>Marketing approval granted<\/td><td>Macau<\/td><\/tr><tr><td><strong>Jul 2026<\/strong><\/td><td>Real-world clinical study partnership announced<\/td><td>Hong Kong<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Evidence-Based Medicine Enhancement:<\/strong> The collaboration aims to strengthen the clinical evidence base for dorzagliatin specifically in the Hong Kong healthcare context<\/li>\n\n\n\n<li><strong>Personalized Treatment Approach:<\/strong> Combining GVC&#8217;s diagnostic capabilities with Hua Medicine&#8217;s therapeutic innovation enables patient stratification and optimized treatment outcomes<\/li>\n\n\n\n<li><strong>Market Expansion Strategy:<\/strong> Following regulatory approvals across Greater China, this real-world study supports commercial adoption and potential reimbursement negotiations in Hong Kong<\/li>\n\n\n\n<li><strong>Clinical Data Generation:<\/strong> Expected to produce valuable insights on long-term glycemic control, patient response patterns, and real-world effectiveness compared to standard care<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The real-world clinical study represents a significant step toward establishing precision medicine protocols for type 2 diabetes management in Hong Kong, leveraging the unique mechanism of action of dorzagliatin alongside advanced diagnostic tools to potentially improve patient outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hua Medicine (HKG: 2552) announced a research collaboration agreement with GemVCare (GVC), a Hong Kong-based&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69405,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1159,308],"class_list":["post-69397","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-2552","tag-hua-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hua Medicine (HKG: 2552) announced a research collaboration agreement with GemVCare (GVC), a Hong Kong-based biotechnology company, to conduct a real-world clinical study focused on precision diabetes management using dorzagliatin, a first-in-class glucokinase activator (GKA) anti-diabetic drug, combined with GVC&#039;s precision diagnostic technology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69397\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management\" \/>\n<meta property=\"og:description\" content=\"Hua Medicine (HKG: 2552) announced a research collaboration agreement with GemVCare (GVC), a Hong Kong-based biotechnology company, to conduct a real-world clinical study focused on precision diabetes management using dorzagliatin, a first-in-class glucokinase activator (GKA) anti-diabetic drug, combined with GVC&#039;s precision diagnostic technology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69397\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-06T03:19:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-06T03:23:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69397#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69397\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management\",\"datePublished\":\"2026-07-06T03:19:16+00:00\",\"dateModified\":\"2026-07-06T03:23:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69397\"},\"wordCount\":325,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69397#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0601.webp\",\"keywords\":[\"HKG: 2552\",\"Hua Medicine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69397#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69397\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69397\",\"name\":\"Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69397#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69397#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0601.webp\",\"datePublished\":\"2026-07-06T03:19:16+00:00\",\"dateModified\":\"2026-07-06T03:23:13+00:00\",\"description\":\"Hua Medicine (HKG: 2552) announced a research collaboration agreement with GemVCare (GVC), a Hong Kong-based biotechnology company, to conduct a real-world clinical study focused on precision diabetes management using dorzagliatin, a first-in-class glucokinase activator (GKA) anti-diabetic drug, combined with GVC's precision diagnostic technology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69397#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69397\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69397#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0601.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69397#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management - Insight, China&#039;s Pharmaceutical Industry","description":"Hua Medicine (HKG: 2552) announced a research collaboration agreement with GemVCare (GVC), a Hong Kong-based biotechnology company, to conduct a real-world clinical study focused on precision diabetes management using dorzagliatin, a first-in-class glucokinase activator (GKA) anti-diabetic drug, combined with GVC's precision diagnostic technology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69397","og_locale":"en_US","og_type":"article","og_title":"Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management","og_description":"Hua Medicine (HKG: 2552) announced a research collaboration agreement with GemVCare (GVC), a Hong Kong-based biotechnology company, to conduct a real-world clinical study focused on precision diabetes management using dorzagliatin, a first-in-class glucokinase activator (GKA) anti-diabetic drug, combined with GVC's precision diagnostic technology.","og_url":"https:\/\/flcube.com\/?p=69397","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-06T03:19:16+00:00","article_modified_time":"2026-07-06T03:23:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69397#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69397"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management","datePublished":"2026-07-06T03:19:16+00:00","dateModified":"2026-07-06T03:23:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69397"},"wordCount":325,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69397#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0601.webp","keywords":["HKG: 2552","Hua Medicine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69397#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69397","url":"https:\/\/flcube.com\/?p=69397","name":"Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69397#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69397#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0601.webp","datePublished":"2026-07-06T03:19:16+00:00","dateModified":"2026-07-06T03:23:13+00:00","description":"Hua Medicine (HKG: 2552) announced a research collaboration agreement with GemVCare (GVC), a Hong Kong-based biotechnology company, to conduct a real-world clinical study focused on precision diabetes management using dorzagliatin, a first-in-class glucokinase activator (GKA) anti-diabetic drug, combined with GVC's precision diagnostic technology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69397#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69397"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69397#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0601.webp","width":1080,"height":608,"caption":"Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69397#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0601.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69397"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69397\/revisions"}],"predecessor-version":[{"id":69406,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69397\/revisions\/69406"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69405"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}